Targacept (TRGT) and AstraZeneca (AZN) announce their experimental depression pill failed to show any improvement for patients in a clinical trial. The firms are studying TC-5214 as a potential additional therapy for patients no longer responding to other antidepressants. Premarket: TRGT -50.3%, AZN -3.3%.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/